Share

Amgen Inc. (AMGN.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+54.9%

Includes 1.68% annual net dividend contribution

1. Investment Thesis — Base Case

The central tension is a race between two clocks. One counts down the legacy book

Prolia, XGEVA, Otezla and Enbrel bleeding revenue and price to biosimilars and Medicare negotiation. The other counts up: six growth drivers compounding at 26%, at 29%, and a scheduled amortization runoff that lifts reported earnings without any operating improvement. Base case, the second clock wins narrowly, delivering mid-single-digit non-GAAP EPS growth rather than the stagnation consensus assumes, while MariTide contributes real but discounted value after a mixed-to-good 2027 readout. Investors are paid a 2.6% dividend to wait, with deleveraging restoring repurchases from 2028.
FY2026 non-GAAP midpoint near $22.90 compounding mid-single-digit to roughly $29 by 2031.
A steady 17-18x forward multiple on that base supports a share price near $530-555.
Implied equity near $295B on 544M shares; 4.85% TTM FCF yield cross-checks the valuation path.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-18	216
Observed price	2021-10-09	207
Observed price	2021-10-27	207
Observed price	2021-11-04	214
Observed price	2021-11-09	212
Observed price	2021-11-30	201
Observed price	2021-12-05	207
Observed price	2021-12-26	225
Observed price	2021-12-31	225
Observed price	2022-01-17	231
Observed price	2022-02-08	235
Observed price	2022-02-16	222
Observed price	2022-02-21	221
Observed price	2022-03-06	232
Observed price	2022-03-19	235
Observed price	2022-04-09	251
Observed price	2022-04-18	255
Observed price	2022-05-01	234
Observed price	2022-05-10	240
Observed price	2022-05-27	255
Observed price	2022-06-05	247
Observed price	2022-06-13	237
Observed price	2022-07-09	248
Observed price	2022-07-18	244
Observed price	2022-08-04	247
Observed price	2022-08-17	252
Observed price	2022-08-22	247
Observed price	2022-09-12	235
Observed price	2022-09-21	227
Observed price	2022-10-08	239
Observed price	2022-10-17	249
Observed price	2022-10-30	270
Observed price	2022-11-16	287
Observed price	2022-11-29	285
Observed price	2022-12-04	284
Observed price	2022-12-25	263
Observed price	2022-12-30	261
Observed price	2023-01-07	274
Observed price	2023-01-25	257
Observed price	2023-02-15	240
Observed price	2023-02-20	239
Observed price	2023-03-09	226
Observed price	2023-03-18	230
Observed price	2023-04-08	250
Observed price	2023-04-13	251
Observed price	2023-05-04	232
Observed price	2023-05-08	234
Observed price	2023-05-26	218
Observed price	2023-06-08	221
Observed price	2023-06-21	230
Observed price	2023-06-29	222
Observed price	2023-07-21	234
Observed price	2023-07-30	233
Observed price	2023-08-16	263
Observed price	2023-08-20	259
Observed price	2023-09-02	255
Observed price	2023-09-15	261
Observed price	2023-10-07	270
Observed price	2023-10-11	285
Observed price	2023-10-29	264
Observed price	2023-11-15	272
Observed price	2023-11-19	265
Observed price	2023-12-02	271
Observed price	2023-12-24	282
Observed price	2023-12-28	288
Observed price	2024-01-10	307
Observed price	2024-02-01	317
Observed price	2024-02-14	289
Observed price	2024-02-18	284
Observed price	2024-03-11	275
Observed price	2024-03-28	283
Observed price	2024-04-06	269
Observed price	2024-04-15	265
Observed price	2024-05-02	284
Observed price	2024-05-15	317
Observed price	2024-05-28	301
Observed price	2024-06-14	301
Observed price	2024-06-23	317
Observed price	2024-07-02	311
Observed price	2024-07-15	332
Observed price	2024-07-23	335
Observed price	2024-08-10	323
Observed price	2024-08-31	331
Observed price	2024-09-05	325
Observed price	2024-09-22	335
Observed price	2024-09-26	319
Observed price	2024-10-14	324
Observed price	2024-10-31	316
Observed price	2024-11-04	318
Observed price	2024-11-17	279
Observed price	2024-11-30	281
Observed price	2024-12-22	263
Observed price	2025-01-04	259
Observed price	2025-01-17	271
Observed price	2025-01-21	275
Observed price	2025-02-08	297
Observed price	2025-02-16	294
Observed price	2025-03-10	325
Observed price	2025-03-19	318
Observed price	2025-04-05	295
Observed price	2025-04-22	279
Observed price	2025-05-01	288
Observed price	2025-05-14	271
Observed price	2025-05-27	281
Observed price	2025-06-13	295
Observed price	2025-06-22	274
Observed price	2025-06-26	281
Observed price	2025-07-09	300
Observed price	2025-07-22	309
Observed price	2025-08-09	288
Observed price	2025-08-22	294
Observed price	2025-09-08	280
Observed price	2025-09-25	273
Observed price	2025-10-04	297
Observed price	2025-10-21	299
Observed price	2025-10-26	292
Observed price	2025-11-03	301
Observed price	2025-11-16	340
Observed price	2025-11-29	345
Observed price	2025-12-12	321
Observed price	2025-12-25	332
Observed price	2026-01-03	323
Observed price	2026-01-20	343
Observed price	2026-02-07	372
Observed price	2026-02-20	380
Observed price	2026-03-05	372
Observed price	2026-03-13	371
Observed price	2026-04-04	346
Observed price	2026-04-13	349
Observed price	2026-04-30	332
Observed price	2026-05-17	329
Observed price	2026-05-22	339
Observed price	2026-05-30	332
Observed price	2026-06-21	345
Observed price	2026-06-25	354
Observed price	2026-07-04	370
Observed price	2026-07-21	366
Observed price	2026-08-12	417
Observed price	2026-09-02	444
Observed price	2026-09-07	401
Observed price	2026-09-15	376
Observed price	2026-09-22	410
Observed price	2026-09-25	415
Published advisor forecast	2026-09-18	386
Published advisor forecast	2026-12-18	393
Published advisor forecast	2027-03-18	382
Published advisor forecast	2027-06-18	404
Published advisor forecast	2027-09-18	409
Published advisor forecast	2027-12-18	421
Published advisor forecast	2028-03-18	425
Published advisor forecast	2028-06-18	438
Published advisor forecast	2028-09-18	442
Published advisor forecast	2028-12-18	455
Published advisor forecast	2029-03-18	455
Published advisor forecast	2029-06-18	469
Published advisor forecast	2029-09-18	478
Published advisor forecast	2029-12-18	488
Published advisor forecast	2030-03-18	493
Published advisor forecast	2030-06-18	503
Published advisor forecast	2030-09-18	508
Published advisor forecast	2030-12-18	523
Published advisor forecast	2031-03-18	528
Published advisor forecast	2031-06-18	539
Published advisor forecast	2031-09-18	550

2. Scenarios & Signals

Bull case

The bull case activates when the obesity option stops being free. Clean MARITIME-1/-2 topline in H1 2027 - mid-teens weight loss with tolerable discontinuation rates and working Q8W/Q12W maintenance dosing - converts Amgen from yield asset to cardiometabolic franchise. That re-rating compounds: a higher multiple lowers the cost of equity, below 2x frees repurchases, and the amortization runoff flatters reported EPS simultaneously. Add an IMDELLTRA label expansion and the shares clear $700 well before 2031.

Bear case

The bear case activates when both clocks run against Amgen at once. A tolerability-driven MariTide disappointment in 2027 vaporizes the growth narrative just as the second and third CMS negotiation cohorts strike Otezla and successor products, while denosumab erosion persists longer than modeled. The multiple compresses toward low-teens ex-growth pharma, refinancing at 5% coupons erodes coverage, and repurchases stay suspended to protect leverage. Shares would revisit the low $300s and stay there.

Current crowd narrative

The consensus trades Amgen as a bond proxy with a lottery ticket stapled on: a 2.6% dividend, defensible cash flow, an IRA-impaired legacy book, and MariTide treated as free optionality after the 2024 tolerability scare. Sell-side anchors on roughly 1.9% forward [24], treating erosion and price-setting as settled fact while quietly discounting the 26% growth-driver compounding.

Alpha-gap assessment

The crowd modestly underestimates these shares, implying underpricing. Two pieces of evidence are being ignored. First, the 24x trailing GAAP multiple versus ~17x forward non-GAAP is not a quality gap; it is a scheduled amortization runoff from $3.6B in 2027 to $2.1B in 2031 [4], mechanical and non-cash. Second, nearly 70% of product sales now grow at 26% [5], meaning the erosion base is shrinking as a share of revenue. The market prices the decline and rents the growth for free.

Convergence catalyst

MARITIME-1 and MARITIME-2 topline in H1 2027, following the early-2027 primary completion dates [11], is the single event that forces re-underwriting. The first observable sign of repricing is options-implied volatility collapsing after the print with the shares holding above $400, indicating the obesity option was repriced rather than expired.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.1
Expected volatility regime: moderate
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Growth Engine Outruns THE Erosion	Follow the product-line evidence, not the patent-cliff headline: six growth drivers grew 26% year-over-year in Q2 2026 and now represent nearly 70% of product sales [5], with Repatha $953M (+37%), EVENITY $714M (+38%) and TEZSPIRE $486M (+42%) more than covering Prolia and XGEVA declines [3]. That mix shift lifted total revenue 10% to $10.05B and forced a guidance raise to $38.2-39.4B [1][23]. The arithmetic persists while these franchises remain pre-LOE.	Not available	+22.0%
THE Amortization Cliff Nobody Models	Here is the mechanical bridge the crowd ignores: the Q1 2026 10-Q schedules finite-lived intangible amortization falling from $3.6B in 2027 to $2.3B in 2029 and $2.1B in 2031 [4]. That is a pre-committed, non-cash charge running off, so GAAP earnings converge toward the non-GAAP line without a single operating improvement. It compresses the 24x trailing GAAP multiple toward the ~17x forward non-GAAP multiple purely through accounting gravity.	Not available	+12.0%
Deleveraging BUYS BACK THE Buyback	Horizon debt discipline is quietly restoring optionality. Long-term debt of roughly $51.9B at 30 June 2026 was down 3.5% year-over-year against $14.0B cash and $16.5B TTM EBITDA, implying roughly 2.3x net leverage [20][2] - well below the 3.6x figure circulating in secondary commentary [21]. Interest coverage improved to 4.26x in FY2025 from 2.46x. Zero 2025 repurchases were a choice; as leverage normalizes, share count reduction returns as an EPS lever.	Not available	+10.0%
Biosimilars AS A Second CASH Engine	The unit that was supposed to cannibalize Amgen is now compounding for it: the biosimilars portfolio grew 29% year-over-year with PAVBLU up 121% [5]. This is Amgen exploiting its own manufacturing scale and payer relationships against rivals' originator franchises, converting process engineering into gross profit at lower R&D risk than novel discovery. The pipeline of future biosimilar candidates gives the segment visible multi-year runway as blockbuster biologics lose exclusivity through 2031.	Not available	+8.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
IRA Price Setting ONE Cohort AT A TIME	The evidence is already in the income statement, and it is a price event rather than a volume event: Enbrel fell 4% overall while net selling price dropped 22%, attributed to Medicare Part D price-setting effective 1 January 2026 plus richer 340B mix [6]. CMS negotiates 15 more drugs for 2027, 15 for 2028 and 20 annually from 2029 [7]. Each cohort strips high-margin revenue with no offsetting cost, so the drag compounds across the horizon.	Not available	-18.0%
Denosumab Erosion IS NOT Finished	Biosimilar entry into Amgen's own bone franchise is running hot: Prolia fell 32% to $759M and XGEVA 34% to $352M in Q2 2026, with Otezla down 21% [3]. Combined, that legacy block shed well over $700M of annualized high-margin revenue in a single year. Erosion curves for biologics typically extend three to four years past first entry, so this drags reported growth through at least 2028 before the base effect exhausts itself.	Not available	-15.0%
Third TO A TWO Horse Obesity RACE	MariTide arrives into a market where Lilly and Novo already own prescriber habit, payer contracts and manufacturing scale, and where oral agents are compressing the price umbrella. Amgen's differentiator is monthly-or-less dosing, not superior efficacy; Phase 2 delivered 12.3% to 16.2% mean weight loss at week 52 versus 2.5% placebo [13], respectable but not category-defining. Commercial share capture therefore requires discounting, which caps the revenue contribution investors currently imagine.	Not available	-10.0%
Refinancing AT THE NEW Coupon	Amgen issued $4.0B of notes in Q1 2026 at 4.20% through 5.50% coupons [17], well above the legacy stack it replaces, with the US 10-year at 4.998% on 18 September 2026 and the Fed at 3.75-4.00%. Against roughly $51.9B of long-term debt [20], every refinancing tranche converts a low-coupon liability into a higher one. It is a slow-burn interest-expense headwind and simultaneously raises the discount rate applied to a defensive cash flow.	Not available	-8.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Maritide Lands Clean IN 2027	MARITIME-1 (3,500 participants) and MARITIME-2 (999, with type 2 diabetes) carry primary readout dates at the start of 2027 [11]. The 72-week design titrates 21mg to 35mg to 70mg over eight weeks specifically to suppress the Phase 2 GI discontinuations [12]. If topline in H1 2027 shows mid-to-high-teens weight loss with discontinuation rates near incumbents, plus the Q8W/Q12W maintenance arms working, the market reprices Amgen from a yield asset to a cardiometabolic growth franchise. It stays below 50% because tolerability, not efficacy, is the documented vulnerability.	35.0%	+30.0%
Oncology AND RARE Disease Compound Faster	UPLIZNA at $262M and IMDELLTRA at $258M both more than doubled year-over-year in Q1 2026 [4]. A first-line small-cell lung cancer label expansion for IMDELLTRA, combined with dazodalibep Sjogren's Phase 3 data expected in H2 2026 [2] and broader UPLIZNA indications, could add a multi-billion-dollar annual revenue tier by 2029-2030 that the current 17x forward multiple does not contemplate. Below 50% because oncology label expansions face competitive readouts and Sunakiment already missed a Phase 2 primary endpoint [2], evidencing live pipeline attrition.	30.0%	+14.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
MFN Jumps THE Medicare Fence	The August 2026 agreements, which include Amgen, mainly touch Medicaid and cash-pay and delivered a three-year tariff suspension in exchange [9][10] - a cheap concession on a low revenue base. The risk is escalation: an executive or legislative extension of most-favored-nation reference pricing into Medicare Part B/D or commercial books between 2028 and 2030, plausibly after an election cycle, would reprice the profit pool rather than trim its edges. Below 50% because such reach invites litigation and congressional resistance, as current scrutiny already shows [8].	28.0%	-20.0%
Tolerability Sinks THE Obesity Thesis	The Phase 3 titration scheme exists because Phase 2 produced high GI-driven discontinuations [12]. If MARITIME-1/-2 topline in H1 2027 shows completion rates materially below tirzepatide and semaglutide benchmarks, or efficacy that fails to clear the mid-teens bar, the obesity option collapses to near zero and the multiple compresses toward a low-teens ex-growth pharma. Amgen has already discontinued AMG 513 in Phase 1 obesity [2], evidence the program carries real attrition. Below 50% because the titration redesign directly targets the known failure mode.	35.0%	-18.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_e1d81625-42ee-563e-82de-e1b00433e37e__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+2.0%	393.36	Q3 print confirms the raised $38.2-39.4B guidance and the MFN agreement removes the tariff overhang. Defensive rotation away from stretched AI valuations supports the bid, but a 5% ten-year caps multiple expansion.
2	March 18, 2027	-3.0%	381.56	February 2027 guidance shows near-flat non-GAAP EPS as Part D price-setting compounds on Enbrel and the next negotiation cohort lands. Event-risk trimming ahead of the MariTide readout pressures the shares.
3	June 18, 2027	+6.0%	404.46	MARITIME-1 and -2 topline arrives. Base case delivers mid-teens weight loss with titration-improved but imperfect tolerability, enough to reprice the obesity option upward without triggering a full growth re-rating.
4	September 18, 2027	+1.0%	408.50	Post-readout consolidation as investors parse discontinuation subgroup data and await regulatory filing detail. Restrictive Fed policy and a firm dollar keep the defensive multiple anchored near seventeen times forward earnings.
5	December 18, 2027	+3.0%	420.76	The 2028 setup improves visibly as scheduled amortization steps down from $3.6B to $2.8B, lifting reported earnings. Management signals repurchase resumption as net leverage approaches two times EBITDA.
6	March 18, 2028	+1.0%	424.96	The second CMS negotiation cohort takes effect and is already discounted. Guidance is workmanlike; denosumab erosion continues but its shrinking revenue share reduces the drag on consolidated growth.
7	June 18, 2028	+3.0%	437.71	MariTide launch preparation and regulatory milestones advance while UPLIZNA and IMDELLTRA scale toward blockbuster run-rates. Easing inflation allows modest multiple recovery across defensive large-cap pharmaceuticals.
8	September 18, 2028	+1.0%	442.09	Prolia and XGEVA erosion troughs, removing a persistent revenue headwind. Offsetting this, US election-cycle drug-pricing rhetoric revives most-favored-nation escalation fears and caps sector valuations.
9	December 18, 2028	+3.0%	455.35	Obesity approval and initial launch economics land alongside net leverage falling below two times. Repurchases resume meaningfully, reducing share count and adding a direct per-share earnings lever.
10	March 18, 2029	+0.0%	455.35	Launch spending compresses near-term margins while Lilly's oral franchise pressures obesity pricing. The twenty-drug annual negotiation cadence begins, offsetting commercial momentum and holding the shares flat.
11	June 18, 2029	+3.0%	469.01	Prescription data validates the monthly-or-less dosing niche among adherence-challenged patients. Amgen carves a defensible minority share rather than leadership, which is enough to beat depressed revenue expectations.
12	September 18, 2029	+2.0%	478.39	Amortization falls to roughly $2.3B, converging GAAP toward non-GAAP earnings and compressing the headline multiple mechanically. Stable rates and resilient US healthcare spending support the defensive allocation.
13	December 18, 2029	+2.0%	487.96	MARITIME-CV outcomes enrollment matures and cardiovascular label optionality enters models. Biosimilar launches against newly expiring originator biologics add incremental, low-risk gross profit to the base.
14	March 18, 2030	+1.0%	492.84	The full twenty-drug-per-year negotiation cadence bites the mature portfolio, trimming net pricing. Growth-driver revenue now dominates the mix, limiting damage but capping guidance ambition for the year.
15	June 18, 2030	+2.0%	502.70	Free cash flow conversion improves as launch investment normalizes and interest expense stabilizes post-refinancing. Buybacks and a rising dividend deliver most of the incremental shareholder return this quarter.
16	September 18, 2030	+1.0%	507.72	Competitive obesity entrants from smaller biotechs compress pricing expectations sector-wide. Amgen's diversified base absorbs the pressure, but the shares gain only modestly against a neutral macro backdrop.
17	December 18, 2030	+3.0%	522.96	A cardiovascular or sleep-apnea indication expansion broadens the MariTide addressable market. Combined with amortization near $2.2B, reported earnings inflect upward and the market extends the valuation.
18	March 18, 2031	+1.0%	528.18	Enbrel exclusivity questions and the next negotiation cohort resurface as headline risk. Solid guidance and a materially reduced share count limit downside to a modest single-digit advance.
19	June 18, 2031	+2.0%	538.75	The company enters the horizon's final stretch with cleaner economics: lower leverage, converged GAAP earnings and a diversified revenue base less dependent on any single negotiated product.
20	September 18, 2031	+2.0%	549.52	Terminal-period positioning reflects a mid-single-digit EPS compounder trading near eighteen times forward earnings, with the obesity franchise contributing real but non-transformational revenue to the consolidated base.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Amgen posts Q2 2026 revenue of $10.1 billion | AMGN 8-K Filingstocktitan.net
[2]Amgen Lifts 2026 Outlook After Q2 Earnings Beat, Ditches Early-Stage Obesity Drug — BigGo Financefinance.biggo.com
[3]AMGEN INC - Form 10-Q - FY2026sec.gov
[4]AMGEN INC - Form 10-Q - FY2026sec.gov
[5]Amgen Inc (AMGN) (Q2 2026) Earnings Call Highlights: Revenue Surges Past $10 Billion, Guidance ...finance.yahoo.com
[6]Amgen results show biosimilars and IRA pricing reshaping drug spend | Insurance Businessinsurancebusinessmag.com
[7]Drug companies sign "Most Favored Nation" deals, then raise prices anywaydrugdiscoverytrends.com
[8]Most-Favored-Nation Drug Pricing Policy: Executive Actions, Manufacturer Agreements, and Growing Congressional Scrutiny | Insights | Sidley Austin LLPsidley.com
[9]Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
[10]Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy | Pharmacy Timespharmacytimes.com
[11]Amgen enters Maritime, launching 2 late-stage obesity trials for MariTidefiercebiotech.com
[12]Amgen's phase 3 MariTide study will titrate doses to quell nauseafiercebiotech.com
[13]MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes | Applied Clinical Trials Onlineappliedclinicaltrialsonline.com
[14]amgen reports first quarter 2026 financial resultssec.gov
[15]Amgen Details Phase 3 Sleep Apnea Studies for Investigational Drug MariTide | Sleep Reviewsleepreviewmag.com
[16]Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?finance.yahoo.com
[17]Form 10-Q for Amgen INC filed 05/01/2026investors.amgen.com
[18]Amgen Inc Earnings - Analysis & Highlights for Q2 2026alpha-sense.com
[19]AMGN Q2 Deep Dive: Broad Portfolio Powers Guidance Upgrade, Pipeline Progress Remains Focus - StockStorystockstory.org
[20]Amgen Long Term Debt 2012-2026 | AMGN | MacroTrendsmacrotrends.net
[21]Amgen SWOT Analysis – businessmodelcanvastemplate.combusinessmodelcanvastemplate.com
[22]Amgen (AMGN) Stock Analysis — Quality Score & Fair Valuebeanvest.com
[23]Amgen outlines raised 2026 guidance of $38.2B-$39.4B revenue and $22.30-$23.50 non-GAAP EPS as CFO transition nears (NASDAQ:AMGN) | Seeking Alphaseekingalpha.com
[24]Amgen (NASDAQ:AMGN) Delivers Strong Q2 CY2026 Numbers, Guides for Strong Full-Year Salesfinance.yahoo.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Superintelligence — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.